Randomized trial showing equivalent efficacy of filgrastim 5 μg/kg/d and 10 μg/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1730-1735

  Stahel, R A ^a   Jost, L M ^a   Honegger, H ^a   Betts, E ^a   Goebel, M E M ^a   Nagler, A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030900120     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1730     Document Type: Article

References (15)

1. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1555, 1995
2. Linen DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLL randomized trial. Lancet 341:1051-1054, 1993
3. Stahel RA, Lorenz MJ, Pichert G, et al: High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas. Cancer Treat Rev 21:3-32, 1995
4. Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin lymphomas in first complete remission: A study of 464 patients. J Clin Oncol 6:445-451, 1994
5. Jost LM, Jacky E, Domman-Scherrer, et al: Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. Ann Oncol 6:445-451, 1995
6. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
7. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 326:269-270, 1992
8. Stahel RA, Jost ML, Cerny T, et al: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 12:1931-1938, 1994
9. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327:28-35, 99-106, 1992
10. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
11. Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357, 1996
12. Gisselbrecht C, Prentice HG, Bacigalupo A, et al: Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 343:696-700, 1994
13. Linch DC, Scarffe H, Proctor S, et al: Randomised, vehicle controlled, dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 11:307-311, 1993
14. Garcia-Conde J, Zubizarreta A, Bueno J, et al: A randomised, open-label, multicentre, parallel group study comparing two dose levels of G-CSF (filgrastim) following high-dose chemotherapy (HDC) and autologous BMT (ABMT) in patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Presented at the 21st Annual Meeting of the European Bone Marrow Transplantation Group and 11th Meeting of the Nurses Group. Davos, Switzerland, March 19-23, 1995, pS95 (abstr 400)
15. Hartmann O, Biaise D, Michon J, et al: Results of a multicentric randomised clinical trial comparing peripheral blood stem cells (PBSC) and bone marrow (BM) graft in autologous transplantation. Blood 86:459a, 1995 (suppl 1; abstr 1821)